The feasibility study of docetaxel in patients with anaplastic thyroid cancer

Kenji Kawada, Koichi Kitagawa, Sachi Kamei, Megumi Inada, Ayako Mitsuma, Masataka Sawaki, Toyone Kikumori, Yasushi Fujimoto, Hiroshi Arima, Tsuneo Imai, Yuichi Ando

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

There is no established chemotherapy for anaplastic thyroid cancer. We conducted a prospective feasibility study at a single center to explore the antitumor activity of docetaxel against anaplastic thyroid cancer. Docetaxel was administered intravenously at a dose of 60 mg/m2 over the course of 1 h every 3 weeks in patients with anaplastic thyroid cancer who had received no prior chemotherapy. A total of seven patients with anaplastic thyroid cancer were enrolled over the course of 30 months and received docetaxel. The treatment response was complete response in one patient, stable disease in two and progressive disease in four. The response rate was 14%, and the disease control rate (complete response plus stable disease) was 43%. The median time to progression was 6 weeks (range, 1-50). Toxicity was tolerable. Docetaxel could be an effective drug for the treatment of anaplastic thyroid cancer, with tolerable toxicity.

Original languageEnglish
Article numberhyq025
Pages (from-to)596-599
Number of pages4
JournalJapanese journal of clinical oncology
Volume40
Issue number6
DOIs
Publication statusPublished - 03-03-2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'The feasibility study of docetaxel in patients with anaplastic thyroid cancer'. Together they form a unique fingerprint.

  • Cite this

    Kawada, K., Kitagawa, K., Kamei, S., Inada, M., Mitsuma, A., Sawaki, M., Kikumori, T., Fujimoto, Y., Arima, H., Imai, T., & Ando, Y. (2010). The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Japanese journal of clinical oncology, 40(6), 596-599. [hyq025]. https://doi.org/10.1093/jjco/hyq025